Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus

Antimicrob Agents Chemother. 1998 Apr;42(4):808-12. doi: 10.1128/AAC.42.4.808.

Abstract

We used population analysis techniques to determine zidovudine (ZDV) pharmacokinetic parameters in 15 preterm neonates (mean gestational age, 29.4 weeks; mean birth weight, 1,230 g) at a mean age of 5.5 days. The values of the pharmacokinetic parameters were as follows: clearance, 2.53 +/- 0.44 ml/min/kg; volume of distribution, 1.59 +/- 0.51 liters/kg; and half-life, 7.2 +/- 1.5 h. For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found. The ZDV clearance is low and the half-life is prolonged in premature neonates, but the clearance increases and the half-life decreases with postnatal age. Potentially toxic concentrations may accumulate in serum if the standard dosage for full-term infants is used. We suggest that initial ZDV dosing should be reduced to 1.5 mg every 12 h for preterm neonates.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aging / metabolism
  • Antiviral Agents / pharmacokinetics*
  • Female
  • Gestational Age
  • HIV Infections / metabolism*
  • Half-Life
  • Humans
  • Infant, Newborn
  • Infant, Premature / metabolism*
  • Male
  • Zidovudine / pharmacokinetics*

Substances

  • Antiviral Agents
  • Zidovudine